Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart

From Apr 2019 to Apr 2024

TIDMAVO

RNS Number : 3262G

Advanced Oncotherapy PLC

26 May 2017

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Update on Bracknor financing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has drawn down the third tranche of GBP1.3 million (less 5%, in accordance with terms for receipt of 95% of nominal value of each tranche), for proceeds of GBP1.235 million.

 
  Advanced Oncotherapy Plc                www.avoplc.com 
  Dr. Michael Sinclair,            Tel: +44 20 3617 8728 
   Executive Chairman 
  Nicolas Serandour, CEO 
 
  Stockdale Securities (Nomad 
   & Joint Broker) 
  Antonio Bossi / David            Tel: +44 20 7601 6100 
   Coaten 
 
  Stifel Nicolaus Europe 
   (Joint Broker) 
  Jonathan Senior / Ben            Tel: +44 20 7710 7600 
   Maddison 
 
  Walbrook PR (Financial        Tel: +44 20 7933 8780 or 
   PR & IR)                           avo@walbrookpr.com 
  Paul McManus / Anna Dunphy     Mob: +44 7980 541 893 / 
                                   Mob: +44 7876 741 001 
 

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPGUWWAUPMUAQ

(END) Dow Jones Newswires

May 26, 2017 02:01 ET (06:01 GMT)